Full Text
Abstract
Introduction. Stroke and/or paresis of lower extremities are one of the main risks of venous thromboembolic complications (VTE) not associated with trauma and surgery. At the same time, there is still no generally accepted effective and safe scheme of VTE prophylaxis for patients with hemorrhagic stroke.
The aim of study was to evaluate the efficacy and safety of prophylaxis of deep vein thrombosis of lower extremities and pulmonary embolism with drug Fluxum®.
Materials and methods. We examined 60 patients with hemorrhagic stroke: group 1 (n{={30) — patients received Parnaparin at dose 0,3 ml subcutaneously once a day, starting from the second day after the disease onset; group 2 (n{={30) — patients received other low molecular weight heparins in prophylactic doses also from the second day after the onset of hemorrhagic stroke (Enoxaparin at dose 0,4 ml once a day, Nadroparin at dose 0,3 ml once a day).
Results. It was shown that in patients with hemorrhagic stroke the usage of a new low molecular weight heparin — Parnaparin (Fluxum®, Alfa Wassermann, Italy) at dose of 0,3 ml subcutaneously once a day was equally effective for prophylaxis of deep vein thrombosis as therapy with other low-molecular heparins, and risk of hemorrhagic complications not increased.
Conclusion. Fluxum® usage may be an acceptable alternative of other low molecular weight heparins usage for prevention of VTE in patients with hemorrhagic stroke.